SCHEMBL17455950

SCHEMBL17455950

CCN1CCC(Oc2ccccc2-c2ccncc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CHRM3 P20309 2/20 0.49
▸ IKBKB O14920 2/20 0.46
▸ CHUK O15111 2/20 0.46
▸ HRH1 P35367 1/20 0.44
▸ HRH3 Q9Y5N1 3/20 0.44
▸ ALDH1A1 P00352 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ TDP1 Q9NUW8 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ NMT1 P30419 1/20 0.39
▸ EPHX2 P34913 1/20 0.39
▸ ADRA2A P08913 1/20 0.39
▸ ADRA2B P18089 1/20 0.39
▸ ADRA2C P18825 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17456016 0.85 HRH1 (0.43) IKBKBCHUKHRH1SMN1; SMN2LMNA
SCHEMBL17456031 0.85 SMN1; SMN2 (0.49) CHRM3IKBKBCHUKHRH1ALDH1A1
SCHEMBL17455938 0.84 SMN1; SMN2 (0.57) HRH1HRH3KMT2AMEN1SMN1; SMN2
SCHEMBL17455983 0.81 ALDH1A1 (0.50) ALDH1A1KMT2AKDM4ESMN1; SMN2LMNA
SCHEMBL21238929 0.81 CCNT1 (0.48) CHRM3IKBKBCHUKALDH1A1KMT2A
SCHEMBL17456036 0.81 CDK9 (0.48) CHRM3IKBKBCHUKALDH1A1KMT2A
SCHEMBL17455967 0.80 SCN9A (0.51) CHRM3ALDH1A1KDM4ESMN1; SMN2TDP1
SCHEMBL17455948 0.80 SCN9A (0.52) IKBKBCHUKHRH1ALDH1A1KDM4E
SCHEMBL17456058 0.80 SCN9A (0.49) IKBKBCHUKSMN1; SMN2TDP1
SCHEMBL17505978 0.79 IKBKB (0.64) IKBKBCHUKEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2982666-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-08-07 — — EP disclosed
EP-2982666-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-08-07 — — EP disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
EP-2982666-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-02-10 — — EP disclosed
EP-2982666-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-02-10 — — EP disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024049-A1 HETEROCYCLIC COMPOUND PSEN1, PSEN2, BACE1 CHRM3 1341/4885IKBKB 2723/4885CHUK 1104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback